Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to help advance cancer care. During the first three years of the collaboration, Lilly has been allowed access to expertise within Dana-Farber to further develop multiple pre-clinical and clinical compounds in Lilly’s pipeline, including new indications, novel combinations, and biomarker strategies. This collaboration has fostered ideas, communication and feedback in pre-clinical and clinical study design, process and execution. Under the agreement, Dana-Farber researchers were, and will continue to be, granted permission to conduct independent pre-clinical and clinical studies on select Lilly compounds. All compounds evaluated through this collaboration will continue to be fully owned by Lilly. Financial terms of the agreement were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.